Drug intelligence / Profile preview

cannabidiol + red algae

Development stage
Unknown
Modality
Small Molecules
Administration
Oral
01

Overview

Cannabidiol + red algae is a combination product consisting of two main components: **cannabidiol (CBD)**, a non-psychoactive cannabinoid from Cannabis sativa, and **red algae** extracts, typically derived from marine red algae species such as Lithothamnion calcareum. **Cannabidiol acts on multiple molecular targets** including cannabinoid receptors (CB1 and CB2), serotonin 5-HT1A receptors, TRPV1 channels, and several cytochrome P450 enzymes, leading to diverse effects including anxiolytic, anticonvulsant, antipsychotic, antioxidant, and immunomodulatory actions[1]. **Red algae** are primarily included in supplements for their mineral content (especially calcium and magnesium), bioactive polysaccharides, and potential anti-inflammatory effects; they are not known to directly target human proteins but may modulate inflammation and immune response through their polysaccharide and mineral components. This exact combination is marketed in some dietary supplements for claimed synergistic effects on joint health, inflammation, and overall wellness, but has not been established as a pharmaceutical preparation. Both components are extensively sold as dietary supplements but are not approved together as a pharmaceutical drug for any condition. The **mechanism of action** of the combination is presumed additive: CBD provides neuromodulation and anti-inflammatory effects through receptor interactions, while red algae supplies minerals and possible immune modulation[1].

Other names
cannabidiol + Gigartina red algaecannabidiol + red algaeCBD + Gigartina red algae extract
02

Targets

HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))CNR1 (Cannabinoid receptor 1)FAAHGPR55 (G protein-coupled receptor 55)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)TRPV1 (Transient receptor potential cation channel subfamily V member 1)HTR2A (Serotonin receptor 5-HT2A)HTR3A (5-hydroxytryptamine receptor 3A)GLRA3 (Glycine receptor alpha-3 subunit)

Beyond the preview

Go deeper on cannabidiol + red algae.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cannabidiol + red algae.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call